OPKO Health Narrows Q2 Loss to $8.4M as Pharma Segment Turns Profitable
OPK sits 44% above its 52-week low of $0.977.
Summary
OPKO Health reported a sharply narrower Q2 2026 net loss of $8.4 million, with the pharmaceutical segment turning profitable and the diagnostics segment boosted by a one-time earnout. The results mark a significant step toward financial stabilization.
Key Events · Earnings and Guidance · OPK
-
Net Loss Narrows to $8.4M
Q2 2026 net loss was $8.4 million, a 94% improvement from $148.4 million in Q2 2025, driven by higher IP revenue and lower interest expense.
-
Pharma Segment Turns Profitable
The pharmaceutical segment posted operating income of $0.8 million vs a $28.7 million loss last year, boosted by $29.4 million in revenue from Nicoya equity and higher NGENLA royalties.
-
Diagnostics Segment Swings to Profit
Diagnostics operating income was $4.8 million vs a $18.2 million loss, helped by an $18.4 million earnout from the Labcorp oncology sale and cost reductions.
-
Cash Position Remains Strong
Cash, equivalents, and restricted cash totaled $314.4 million at June 30, 2026, down from $369.1 million at year-end 2025, with $62.8 million used in operations during H1 2026.
Analysis · OPK · Life Sciences
A dramatic year-over-year improvement marks OPKO Health's Q2 2026 results, with the net loss shrinking to $8.4 million from $148.4 million. The pharmaceutical segment swung to an operating profit of $0.8 million, driven by a $29.4 million revenue boost from an equity stake in Nicoya and higher royalties. The diagnostics segment also turned profitable, aided by an $18.4 million earnout from the Labcorp sale. With $314.4 million in cash and a much-reduced cash burn, the company's near-term survival risk has diminished significantly, though the core business remains unprofitable on an operating basis.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1625 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OPK was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $936.3M. The 52-week trading range was $0.98 to $1.61. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.